Neuphoria Therapeutics Inc.

12/17/2025 | Press release | Distributed by Public on 12/17/2025 15:02

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On December 12, 2025, the Company held an Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the four proposals described below. The proposals presented at the Annual Meeting are described in detail in the Definitive Proxy Statement filed with the Securities and Exchange Commission on November 24, 2025.

Of the 2,357,613 shares of Common Stock outstanding and entitled to vote at the Annual Meeting, 937,447, or 39.76%, of the outstanding and eligible shares, were present either in person or by proxy and entitled to vote on all proposals. Holders of Common Stock voted one vote per share on all matters properly brought before the Annual Meeting.

The results for each of the proposals submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal No. 1 - Election of two class I directors for a three-year term

With respect to the proposal for the election of two Class I directors for a three year term, the voting with respect to Proposal 1 was as follows:

Nominee For Withheld
Peter Miles Davies 759,850 152,879
David Wilson 758,571 154,164
Stephen Doberstein 136,780 775,959
Kimberly Smith 136,740 775,997

Proposal No. 2 - Ratify the appointment of our auditor for the fiscal year ended June 30, 2026

With respect to the proposal to ratify the appointment of Wolf & Company P.C. as our independent registered public accounting firm for the fiscal year ending June 30, 2026, the voting with respect to Proposal 2 was as follows:

For Against Abstain
807,022 96,245 34,180
Neuphoria Therapeutics Inc. published this content on December 17, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 17, 2025 at 21:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]